دورية أكاديمية
أعرض في EDS

Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore.

التفاصيل البيبلوغرافية
العنوان: Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore.
المؤلفون: Boisseau S; Mundipharma Singapore Holding Pte Limited, Singapore., Qasuri M; Mundipharma Singapore Holding Pte Limited, Singapore., Ho WT; Mundipharma Singapore Holding Pte Limited, Singapore., Ghosh W; Costello Medical Singapore Pte Ltd, Singapore., Hadjiat Y; Mundipharma Singapore Holding Pte Limited, Singapore.
المصدر: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2020 Oct 06; Vol. 12, pp. 567-577. Date of Electronic Publication: 2020 Oct 06 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101560564 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6981 (Print) Linking ISSN: 11786981 NLM ISO Abbreviation: Clinicoecon Outcomes Res Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Auckland, NZ : Dove Medical Press
مستخلص: Purpose: Reducing the risk of exacerbation is a long-term goal of managing moderate-to-severe asthma. The use of fluticasone propionate/formoterol fumarate dihydrate (FP/FORM) pressurized metered-dose (pMDI, Flutiform ® ), a type of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) fixed-dose combination, has been associated with lower oral corticosteroid-requiring exacerbation rates than other ICS/LABA fixed-dose combinations, fluticasone propionate/salmeterol xinafoate (FP/SAL) and budesonide/formoterol fumarate (BUD/FORM). This study presents the first budget impact analysis of drug and exacerbation management cost savings associated with the increased access to FP/FORM compared to the currently available ICS/LABAs for treating moderate-to-severe asthma in Singapore.
Patients and Methods: A budget impact model showed changes to annual drug and exacerbation costs over 5 years for patients with moderate-to-severe asthma in Singapore, following the inclusion of FP/FORM on a government subsidy list. The eligible patient population was identified based on national statistics data. Different treatment costs pertaining to the population were applied according to the usage data (IQVIA Singapore National Sales Data) for different scenarios. Drug costs were obtained from public-sector hospitals. Exacerbation management costs were obtained from literature searches.
Results: The analysis showed that increased access to FP/FORM as a result of switching from FP/SAL could help achieve drug (S$1,042,289) and exacerbation management (S$223,550) cost savings over 5 years. In the scenario where patients switched from BUD/FORM, greater drug (S$2,572,797) and exacerbation management (S$256,781) cost savings were observed over 5 years.
Conclusion: The analysis provides a perspective that the increased access to FP/FORM could help achieve drug and exacerbation cost savings for the treatment of moderate-to-severe asthma.
Competing Interests: Sebastien Boisseau, Murtaza Qasuri, Weng Tong Ho and Yacine Hadjiat are employees of Mundipharma Singapore Holding Pte Limited, Singapore. Wrik Ghosh was an employee of Costello Medical Singapore Pte Ltd, Singapore during the development of the model and manuscript. The authors report no other conflicts of interest in this work.
(© 2020 Boisseau et al.)
References: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD004106. (PMID: 22161385)
Allergy. 2004 May;59(5):469-78. (PMID: 15080825)
J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1378-1387.e5. (PMID: 28351782)
NPJ Prim Care Respir Med. 2014 Jun 12;24:14009. (PMID: 24921985)
Eur Respir Rev. 2012 Mar 1;21(123):66-74. (PMID: 22379176)
Int Arch Allergy Immunol. 2013;160(1):93-101. (PMID: 22948386)
Eur Respir J. 2016 Mar;47(3):801-9. (PMID: 26647437)
Cochrane Database Syst Rev. 2014 Jan 24;(1):CD003137. (PMID: 24459050)
J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):346-61. (PMID: 27104231)
BMC Pulm Med. 2011 May 23;11:28. (PMID: 21605396)
Respir Med. 2017 Oct;131:166-174. (PMID: 28947024)
J Asthma. 2013 Sep;50(7):783-90. (PMID: 23638955)
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005533. (PMID: 20393943)
Respir Med. 2014 Jul;108(7):983-91. (PMID: 24795277)
J Asthma. 2012 Dec;49(10):1060-70. (PMID: 23102189)
Adv Ther. 2016 May;33(5):794-806. (PMID: 27084726)
Lancet. 2017 Sep 16;390(10100):1211-1259. (PMID: 28919117)
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618796987. (PMID: 30232933)
BMC Pulm Med. 2013 Mar 22;13:15. (PMID: 23517484)
Ann Acad Med Singap. 2017 Mar;46(3):81-83. (PMID: 28417131)
J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):190-9. (PMID: 23098325)
J Asthma Allergy. 2015 Sep 23;8:93-103. (PMID: 26445555)
N Engl J Med. 2011 May 5;364(18):1695-707. (PMID: 21542741)
Respirology. 2017 Aug;22(6):1102-1109. (PMID: 28370985)
Adv Ther. 2012 Nov;29(11):958-69. (PMID: 23081745)
BMC Public Health. 2012 Mar 19;12:204. (PMID: 22429515)
فهرسة مساهمة: Keywords: Fluticasone/formoterol; Flutiform®; ICS/LABA; asthma exacerbation; reimbursement; treatment cost
تواريخ الأحداث: Date Created: 20201029 Latest Revision: 20220417
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7547776
DOI: 10.2147/CEOR.S262267
PMID: 33116696
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-6981
DOI:10.2147/CEOR.S262267